Treatment with romosozumab is linked to improved BMD and a reduced risk for vertebral fractures among postmenopausal women with osteoporosis.

The European Commission (EC) has approved Biocon Biologics’ biosimilars referencing Amgen’s bone disease therapy denosumab.

Celltrion USA launches 2 denosumab biosimilars, Stoboclo and Osenvelt, enhancing treatment options for osteoporosis and ...

The US biosimilar market expands with new denosumab options, enhancing treatment for patients with osteoporosis and ...

Stoboclo and Osenvelt, FDA-approved biosimilars of Prolia and Xgeva, are now available in the U.S. for variois cancers and ...

The denosumab biosimilars Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo) are now available in the US.

Fresenius Kabi’s fifth and sixth biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht) have launched in the ...

The US subsidiary of South Korea-based Celltrion today announced that Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo) ...

Celltrion USA announced that Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo), biosimilars referencing Prolia ...

South Korean biopharmaceutical firm Celltrion said Tuesday that it had released its denosumab biosimilars, Stoboclo and ...

Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® ...